Q32 Bio grabs $60M to kick off human studies for next-gen complement drugs — with some Covid-19 tweaks along the way
For a company that launched in the early months of the pandemic, Q32 Bio had its fair share of run-ins with the new normals under …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
